Abstract
Background
Volume replacement is an essential component of midface rejuvenation. Previously designed alloplastic implants augment bony prominences. The Maxout™ implant was configured to add height to the lowest surface, the canine fossa.
Methods
A random series of patients, from an office-based practice requested midface augmentation. Three of these patients were human immunodeficiency virus (HIV) positive. With the patient under local anesthetic, bilateral Maxout implants were inserted through either an intraoral or an intranasal incision.
Results
All the implants produced a satisfactory aesthetic improvement. In one HIV-positive patient, one implant placed intraorally became infected and required removal. It was replaced 3 months later through the transnasal approach. All the patients had retained their implants 1 year later.
Conclusions
The Maxout implant is easy to insert and remove, aesthetically effective, secured by bone structures, and located in a neutral position. The risk of infection must be considered, especially for HIV-positive patients.
Similar content being viewed by others
References
MS Constantinides SK Galli PJ Miller PA Adamson (2000) ArticleTitleMalar, submalar, and midfacial implants Facial Plast Surg 1 35–44 Occurrence Handle10.1055/s-2000-7324
JQ Owsley Zweifier: (2002) ArticleTitleMidface lift of the malar fat pad: Technical advances Plast Reconstr Surg 110 674–685 Occurrence Handle10.1097/00006534-200208000-00048 Occurrence Handle12142695
OM Ramirez (1999) ArticleTitleBuccal fat pad pedicle for midface augmentation Ann Plast Surg 43 109–118 Occurrence Handle1:STN:280:DyaK1Mzot1WitQ%3D%3D Occurrence Handle10454314